CTOs on the Move

Theradex Oncology Experts

www.theradex.com

 
Theradex is an international contract research organization providing complete professional services for the clinical research and development of pharmaceutical compounds, medical devices and diagnostic tests in the areas of oncology and
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.theradex.com
  • 4365 Us Highway 1 Ste 101
    Princeton, NJ USA 08540
  • Phone: 609.799.7580

Executives

Name Title Contact Details

Similar Companies

Acatris

Acatris Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RW Troxell

RW Troxell is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Haichang

Zhejiang Haichang is a biopharmaceutical company based in Hangzhou, China. They specialize in the development of mRNA vaccines, nucleic acid drug delivery, and lipid nanoparticle technologies.

Cedarburg Hauser Pharmaceuticals

Cedarburg Hauser Pharmaceuticals is a Grafton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.